HemaSphere
(Jun 2022)
P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA
- J. Mei,
- Y. Wang,
- S. Kabir,
- N. Ichikawa,
- S. Iino,
- C. Lebedinsky
Affiliations
- J. Mei
- 1 Clinical Development, Sumitomo Dainippon Pharma Oncology, Inc, Cambridge
- Y. Wang
- 2 Computational Research, Sumitovant Biopharma, New York, United States of America
- S. Kabir
- 1 Clinical Development, Sumitomo Dainippon Pharma Oncology, Inc, Cambridge
- N. Ichikawa
- 3 Oncology Clinical Development Unit, Sumitomo Dainippon Pharma Co., Ltd, Osaka, Japan
- S. Iino
- 3 Oncology Clinical Development Unit, Sumitomo Dainippon Pharma Co., Ltd, Osaka, Japan
- C. Lebedinsky
- 1 Clinical Development, Sumitomo Dainippon Pharma Oncology, Inc, Cambridge
- DOI
-
https://doi.org/10.1097/01.HS9.0000847044.61674.8e
- Journal volume & issue
-
Vol. 6
pp.
934
– 935
WeChat QR code